


Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

Listing of the Claims:

1-16. (Cancelled).

17. (Currently Amended) A compound of formula (I),



the *N*-oxide forms, the ~~addition~~ pharmaceutically acceptable salts and the stereo-chemically isomeric forms thereof, wherein

n is 0, 1 or 2;

X is N or CR⁷, wherein R⁷ is hydrogen or taken together with R¹ may form a bivalent radical of formula -CH=CH-CH=CH-;

R¹ is C₁₋₆alkyl;

R² is hydrogen, hydroxy, C₁₋₆alkyl, or C₃₋₆alkynyl;

R³ is a radical selected from

-(CH₂)_s- NR⁸R⁹ (a-1),

-O-H (a-2),

-O-R¹⁰ (a-3),

-S- R¹¹ (a-4), or

—C≡N (a-5),

wherein

s is 0, 1, 2 or 3;

R⁸, R¹⁰ and R¹¹ are each independently selected from -CHO, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyl, amino, C₁₋₆alkylamino,

di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonylaminoC₁₋₆alkyl,
 piperidiny(C₁₋₆alkylaminocarbonyl, piperidiny(C₁₋₆alkyl,
~~piperidiny(C₁₋₆alkylaminocarbonyl,~~ C₁₋₆alkyloxy, thiophenylC₁₋₆alkyl,
 pyrroly(C₁₋₆alkyl, arylC₁₋₆alkylpiperidiny(C₁₋₆alkyl, arylcarbonylC₁₋₆alkyl,
 arylcarbonylpiperidiny(C₁₋₆alkyl, haloindozolylpiperidiny(C₁₋₆alkyl,
 arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, and

R⁹ is hydrogen or C₁₋₆alkyl;


or R³ is a group of formula




wherein

t is 0, 1, 2 or 3;


-Z is a heterocyclic ring system selected from




(c-1)




(c-3)




(c-5)




(c-6)




(c-7)




(c-8)



(c-9)




(c-10)



(c-11)

wherein R¹² is hydrogen, halo, C₁₋₆alkyl, aminocarbonyl, amino, hydroxy, aryl,




C₁₋₆alkylaminoC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkylamino, arylC₁₋₆alkyl, di(phenylC₂₋₆alkenyl), piperidinyl, piperidinylC₁₋₆alkyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylC₁₋₆alkyl, aryloxy(hydroxy)C₁₋₆alkyl, haloindazolyl, arylC₁₋₆alkyl, arylC₂₋₆alkenyl, arylC₁₋₆alkylamino, morpholino, C₁₋₆alkylimidazolyl, pyridinylC₁₋₆alkylamino; and

R¹³ is hydrogen, piperidinyl or aryl;

R⁴, R⁵ and R⁶ are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C₁₋₆alkyl, C₁₋₆alkyloxy, amino, aminoC₁₋₆alkyl, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy or C₁₋₆alkyloxycarbonyl, or C₁₋₆alkyl substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₆alkyloxy, or aminoC₁₋₆alkyloxy; or

when R⁵ and R⁶ are on adjacent positions they may taken together form a bivalent radical of formula




wherein R¹⁴ is C₁₋₆alkyl;

and aryl is phenyl, phenyl substituted with halo, C₁₋₆alkyl or C₁₋₆alkyloxy.

18. (Previously Presented) A compound as claimed in claim 17 wherein

R³ is a radical selected from the group consisting of (a-1), (a-2), (a-3) (a-5), and (b-1) wherein -Z is a heterocyclic ring system selected from (c-1), (c-6), (c-8), (c-9), or (c-11); s is 0, 1 or 2; R⁸ and R¹⁰ are each independently selected from -CHO, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkylcarbonylaminoC₁₋₆alkyl, piperidinylC₁₋₆alkyl,


piperidinylC₁₋₆alkylaminocarbonyl, C₁₋₆alkyloxy, thiophenylC₁₋₆alkyl, pyrrolylC₁₋₆alkyl, arylC₁₋₆alkylpiperidinyl, arylcarbonylC₁₋₆alkyl, arylcarbonylpiperidinylC₁₋₆alkyl, haloindozolylpiperidinylC₁₋₆alkyl, or arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl; t is 0 or 2; R¹² is hydrogen,




C₁₋₆alkyl, aminocarbonyl, C₁₋₆alkyloxyC₁₋₆alkylamino, di(phenylC₂₋₆alkenyl), piperidinylC₁₋₆alkyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylC₁₋₆alkyl, haloindazolyl, or arylC₂₋₆alkenyl; R⁴, R⁵ and R⁶ are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C₁₋₆alkyl, C₁₋₆alkyloxy, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy or C₁₋₆alkyloxycarbonyl; and when R⁵ and R⁶ are on adjacent positions they may taken together form a bivalent radical of formula (d-1) or (d-2).

19. (Previously Presented) A compound according to claim 17 wherein n is 0; X is CH; R² is hydrogen; Z is a heterocyclic ring system selected from (c-1); t is 2; R¹² is hydrogen; R¹³ is hydrogen; and R⁵ and R⁶ are on adjacent positions and taken together form a bivalent radical of formula (d-2).


20. (Currently Amended) A compound selected from the group consisting of ~~compounds No. 16, compound No. 144, and compound No. 145:~~



[[compound 16]]



[[Compound 144]]



[[Compound 145]]

and

21. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 17.

22. (Cancelled).